A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab or Tremelimumab Alone in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors MedImmune
- 20 Oct 2017 Status changed from active, no longer recruiting to completed.
- 14 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 14 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.